Experimental Antibody Produces Sustained Inflammation Reduction in Patients With Chronic Kidney Disease

Munich, Scientists have reported encouraging results from a clinical trial testing an experimental antibody designed to reduce inflammation in people with chronic kidney disease who also face elevated cardiovascular risk.

The treatment, called pacibekitug, targets interleukin-6 (IL-6), a signalling protein involved in inflammatory processes. Results from the phase 2 TRANQUILITY trial were presented at the European Society of Cardiology Congress 2026 in Munich.

Researchers found that the treatment produced substantial reductions in high-sensitivity C-reactive protein (hs-CRP), an important marker used to measure inflammation, and that the reductions remained visible six months after treatment began.

Why Inflammation Matters in Heart Disease

Doctors have long focused on familiar cardiovascular risk factors such as high blood pressure, diabetes, smoking, obesity and elevated cholesterol.

However, researchers increasingly recognise inflammation as another important contributor to cardiovascular disease.

People with chronic kidney disease can be particularly vulnerable because kidney dysfunction is frequently accompanied by persistent inflammation and a higher risk of cardiovascular complications.

The TRANQUILITY researchers therefore investigated whether directly suppressing an inflammatory pathway could reduce biological signs associated with that risk.

How the TRANQUILITY Trial Was Designed

The study involved 143 adults with stage 3 or 4 chronic kidney disease and elevated hs-CRP levels.

Participants were treated at 49 centres in the United States and were randomly assigned to one of three pacibekitug dosing schedules or a placebo group.

The experimental treatment was administered under the skin at either monthly or three-month intervals, and participants were followed for 180 days.

The average participant was 69 years old, while women represented 64% of the study population.

Around 72% of participants were taking statins, and 59% had diabetes.

Inflammation Marker Fell Sharply

The most notable result involved hs-CRP.

Researchers observed reductions in the marker within the first month of treatment, and those reductions remained sustained through the six-month assessment.

The time-averaged change from baseline was:

• 7% increase with placebo
• 76% reduction with 25 mg pacibekitug every 90 days
• 85% reduction with 50 mg every 90 days
• 89% reduction with 15 mg every 30 days

The differences compared with placebo were statistically significant.

These findings indicate that IL-6 activity can be suppressed for an extended period using the investigational antibody.

Other Cardiovascular Biomarkers Also Changed

The effect was not limited to hs-CRP.

Researchers reported sustained reductions in additional inflammatory markers.

They also observed favourable changes in fibrinogen and lipoprotein(a), two measurements that can be relevant when evaluating cardiovascular risk.

These findings suggest that the biological effect of pacibekitug may extend beyond a single inflammation marker.

However, biomarker improvements should not automatically be interpreted as proof that patients will experience fewer heart attacks or strokes.

Safety Results Were Encouraging

The experimental therapy was generally well tolerated during the six-month study.

Only around 1.9% of participants discontinued treatment, and researchers reported no clear dose-related safety signal.

That is encouraging for a treatment intended to suppress part of the body’s inflammatory response.

Nevertheless, a relatively small phase 2 study cannot identify every possible long-term safety concern.

Larger studies involving more patients and longer follow-up will be needed before the treatment’s overall safety profile can be understood.

The Treatment Is Not Yet Proven to Prevent Heart Attacks

One of the most important limitations of the findings is that the study measured biological markers rather than definitive cardiovascular outcomes.

The trial was not large enough or long enough to determine whether pacibekitug actually prevents heart attacks, strokes, heart failure or cardiovascular deaths.

The investigators themselves say the next step is a larger, longer-term phase 3 study designed to determine whether the reduction in inflammation translates into meaningful improvements in patient outcomes.

A Potential New Approach to Cardiovascular Risk

The research reflects a broader shift in cardiovascular medicine.

Traditional prevention has focused heavily on controlling cholesterol and blood pressure.

Scientists are now investigating whether directly targeting inflammatory pathways can provide additional protection for patients who continue to face significant cardiovascular risk despite standard treatment.

IL-6 is one of the pathways receiving particular attention because genetic, laboratory and clinical research has linked it to cardiovascular disease.

Chronic Kidney Disease Patients Need Better Options

People with moderate-to-severe chronic kidney disease face a disproportionately high burden of cardiovascular disease.

Many already receive standard treatments such as statins and medicines for blood pressure or diabetes.

Yet some patients continue to have elevated inflammatory markers despite these therapies.

The TRANQUILITY findings suggest that targeting inflammation could eventually become another component of cardiovascular risk management for selected kidney disease patients.

That possibility remains hypothetical until outcome-based trials provide stronger evidence.

Why the Six-Month Result Matters

An important feature of the study was the durability of the response.

The treatment did not simply lower hs-CRP temporarily before the marker returned toward its previous level.

Instead, the reduction remained substantial through day 180.

This is particularly relevant because pacibekitug is a long-acting antibody that can be administered relatively infrequently.

If future trials confirm clinical benefits, less frequent dosing could potentially simplify treatment for some patients.

Researchers Now Face the Bigger Question

The key question is no longer whether pacibekitug can reduce inflammation.

The phase 2 findings provide evidence that it can.

The much harder question is whether lowering inflammation through IL-6 inhibition actually changes what happens to patients over the long term.

A successful cardiovascular therapy must ultimately demonstrate benefits that matter to patients—not merely improvements in laboratory measurements.

What Comes Next

The researchers are preparing for the next stage of investigation, which will require substantially larger patient populations and longer follow-up.

Such a study would be designed to determine whether the reduction in inflammatory biomarkers translates into fewer cardiovascular events.

It will also provide more information about long-term safety and help researchers identify which patients are most likely to benefit.

A Promising but Early Result

The TRANQUILITY findings represent an encouraging development in the search for new ways to address cardiovascular risk among people with chronic kidney disease.

Pacibekitug produced large and sustained reductions in inflammation markers without a clear dose-related safety signal in this phase 2 trial.

But the results should be interpreted carefully.

The drug remains investigational, and the trial has not yet demonstrated that it prevents heart attacks, strokes or other cardiovascular events.

The next generation of clinical research will determine whether the impressive laboratory improvements seen in TRANQUILITY can ultimately translate into better health and longer lives for patients.